Do you want to read an article? Please log in or register.
Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis
Inflammatory Bowel Disease
COMMENTED
Related content
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
Am J Gastroenterol.
Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS
doi: 10.1038/s41395-018-0162-0.
Inflammatory Bowel Disease
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis
Clin Gastroenterol Hepatol.
Dulai PS, Singh S, Casteele NV, Meserve J, Winters A, Chablaney S, Aniwan S, Shashi P, Kochhar G, Weiss A, Koliani-Pace JL, Gao Y, Boland BS, Chang JT, Faleck D, Hirten R, Ungaro R, Lukin D, Sultan K, Hudesman D, Chang S, Bohm M, Varma S, Fischer M, Shmidt E, Swaminath A, Gupta N, Rosario M, Jairath V, Guizzetti L, Feagan BG, Siegel CA, Shen B, Kane S, Loftus EV Jr, Sandborn WJ, Sands BE, Colombel JF, Lasch K, Cao C
doi: 10.1016/j.cgh.2020.02.010.
Inflammatory Bowel Disease
Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment
Inflamm Bowel Dis
Lee SH, Walshe M, Oh EH, Hwang SW, Park SH, Yang DH, Byeon JS, Myung SJ, Yang SK, Greener T, Weizman AV, Silverberg MS, Ye BD
doi: 10.1093/ibd/izaa309
Inflammatory Bowel Disease
A simplified definition of histologic improvement in ulcerative colitis and its association with disease outcomes up to 30 weeks from initiation of therapy: Post-hoc analysis of three clinical trials
J Crohns Colitis.
Li K, Strauss R, Marano C, Greenbaum LE, Friedman JR, Peyrin-Biroulet L, Brodmerkel C, De Hertogh G
doi: 10.1093/ecco-jcc/jjz022.
Inflammatory Bowel Disease
Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis
United European Gastroenterol J.
Ochsenkühn T, Tillack C, Szokodi D, Janelidze S, Schnitzler F
doi: 10.1177/2050640619895361.
COMMENTED
Inflammatory Bowel Disease
Complete Resolution of Mucosal Neutrophils Associates With Improved Long-Term Clinical Outcomes of Patients With Ulcerative Colitis
★ 2
Recommended and commented by
PD Dr Luc Biedermann, Faculty Member
doi: 10.1016/j.cgh.2019.12.011.
Inflammatory Bowel Disease
Immunological variables associated with clinical and endoscopic response to vedolizumab in patients with inflammatory bowel diseases
J Crohns Colitis.
Coletta M, Paroni M, Alvisi MF, De Luca M, Rulli E, Mazza S, Facciotti F, Lattanzi G, Strati F, Abrignani S, Fantini MC, Vecchi M, Geginat J, Caprioli F
doi: 10.1093/ecco-jcc/jjaa035.
Inflammatory Bowel Disease
Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review
BMC Gastroenterol.
Helwig U, Mross M, Schubert S, Hartmann H, Brandes A, Stein D, Kempf C, Knop J, Campbell-Hill S, Ehehalt R
doi: 10.1186/s12876-020-01332-w.
RECOMMENDED
Inflammatory Bowel Disease
DUBLIN (Degree of Ulcerative colitis Burden of Luminal INflammation) score, a simple method to quantify inflammatory burden in Ulcerative Colitis
J Crohns Colitis.
Rowan CR, Cullen G, Mulcahy HE, Sheridan J, Moss AC, Ryan EJ,
Doherty GA
doi: 10.1093/ecco-jcc/jjz067.